Semaglutide emerged from Novo Nordisks systematic GLP-1 analogue optimisation programme as the successor to liraglutide , incorporating structural modifications addressing the three principal pharmacokinetic vulnerabilities of native GLP-1: DPP-IV susceptibility at position 8 addressed by Aib8 alpha-aminoisobutyric acid substitution, proteolytic cleavage at position 34 addressed by Arg34Lys substitution, and the short half-life of unmodified GLP-1 analogues addressed by the C18 fatty diacid conjugation providing tighter albumin binding and longer half-life than liraglutides C16 fatty acid, producing the approximately one-week half-life enabling once-weekly subcutaneous administration
This glucose-dependent mechanism is what makes GLP-1 agonists safer than older diabetes drugs that could cause dangerous hypoglycemia
Our product has shown promising results in reducing body weight, improving metabolic health, and minimizing associated risks
even though social media is not necessarily representative, a large collection of posts may reflect additional concerns. Still, the researchers emphasize that these findings do not prove causation
Or you can take control of your health journey today by exploring a direct path that puts you in the driver's seat
